M23-384: A Phase 3 Randomized, Open Label, Multicenter Study to Evaluate the Safety and Efficacy of ABBV-706 versus Standard of Care in Subjects with Relapsed/Refractory Small Cell Lung Cancer (SCLC)

Title
A Phase 3 Randomized, Open Label, Multicenter Study to Evaluate the Safety and Efficacy of ABBV-706 versus Standard of Care in Subjects with Relapsed/Refractory Small Cell Lung Cancer (SCLC)
Principal Investigator
Almubarak, Mohammed
Phase
III
Age Group
Adult
Applicable Disease Sites
Lung Cancer
Participating Institutions
Mary Babb Randolph Cancer Center
Contacts
Rachel Harper
Clinical Research Specialist
Phone: +1 304-293-6066
Email:

View on ClinicalTrials.gov